Jona A Hattangadi-Gluth1, Paul H Chapman2, Daniel Kim3, Andrzej Niemierko3, Marc R Bussière3, Alison Stringham3, Juliane Daartz3, Christopher Ogilvy4, Jay S Loeffler3, Helen A Shih5. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego, California. 2. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Neurosurgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 5. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: hshih@partners.org.
Abstract
PURPOSE/OBJECTIVE(S): To evaluate the obliteration rate and potential adverse effects of single-fraction proton beam stereotactic radiosurgery (PSRS) in patients with cerebral arteriovenous malformations (AVMs). METHODS AND MATERIALS: From 1991 to 2010, 248 consecutive patients with 254 cerebral AVMs received single-fraction PSRS at our institution. The median AVM nidus volume was 3.5 cc (range, 0.1-28.1 cc), 23% of AVMs were in critical/deep locations (basal ganglia, thalamus, or brainstem), and the most common prescription dose was 15 Gy(relative biological effectiveness [RBE]). Univariable and multivariable analyses were performed to assess factors associated with obliteration and hemorrhage. RESULTS: At a median follow-up time of 35 months (range, 6-198 months), 64.6% of AVMs were obliterated. The median time to total obliteration was 31 months (range, 6-127 months), and the 5-year and 10-year cumulative incidence of total obliteration was 70% and 91%, respectively. On univariable analysis, smaller target volume (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.86-0.93, P<.0001), smaller treatment volume (HR 0.93, 95% CI 0.90-0.96, P<.0001), higher prescription dose (HR 1.16, 95% CI 1.07-1.26, P=.001), and higher maximum dose (HR 1.14, 95% CI 1.05-1.23, P=.002) were associated with total obliteration. Deep/critical location was also associated with decreased likelihood of obliteration (HR 0.68, 95% CI 0.47-0.98, P=.04). On multivariable analysis, critical location (adjusted HR [AHR] 0.42, 95% CI 0.27-0.65, P<.001) and smaller target volume (AHR 0.81, 95% CI 0.68-0.97, P=.02) remained associated with total obliteration. Posttreatment hemorrhage occurred in 13 cases (5-year cumulative incidence of 7%), all among patients with less than total obliteration, and 3 of these events were fatal. The most common complication was seizure, controlled with medications, both acutely (8%) and in the long term (9.1%). CONCLUSIONS: The current series is the largest modern series of PSRS for cerebral AVMs. PSRS can achieve a high obliteration rate with minimal morbidity. Post-treatment hemorrhage remains a potentially fatal risk among patients who have not yet responded to treatment.
PURPOSE/OBJECTIVE(S): To evaluate the obliteration rate and potential adverse effects of single-fraction proton beam stereotactic radiosurgery (PSRS) in patients with cerebral arteriovenous malformations (AVMs). METHODS AND MATERIALS: From 1991 to 2010, 248 consecutive patients with 254 cerebral AVMs received single-fraction PSRS at our institution. The median AVM nidus volume was 3.5 cc (range, 0.1-28.1 cc), 23% of AVMs were in critical/deep locations (basal ganglia, thalamus, or brainstem), and the most common prescription dose was 15 Gy(relative biological effectiveness [RBE]). Univariable and multivariable analyses were performed to assess factors associated with obliteration and hemorrhage. RESULTS: At a median follow-up time of 35 months (range, 6-198 months), 64.6% of AVMs were obliterated. The median time to total obliteration was 31 months (range, 6-127 months), and the 5-year and 10-year cumulative incidence of total obliteration was 70% and 91%, respectively. On univariable analysis, smaller target volume (hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.86-0.93, P<.0001), smaller treatment volume (HR 0.93, 95% CI 0.90-0.96, P<.0001), higher prescription dose (HR 1.16, 95% CI 1.07-1.26, P=.001), and higher maximum dose (HR 1.14, 95% CI 1.05-1.23, P=.002) were associated with total obliteration. Deep/critical location was also associated with decreased likelihood of obliteration (HR 0.68, 95% CI 0.47-0.98, P=.04). On multivariable analysis, critical location (adjusted HR [AHR] 0.42, 95% CI 0.27-0.65, P<.001) and smaller target volume (AHR 0.81, 95% CI 0.68-0.97, P=.02) remained associated with total obliteration. Posttreatment hemorrhage occurred in 13 cases (5-year cumulative incidence of 7%), all among patients with less than total obliteration, and 3 of these events were fatal. The most common complication was seizure, controlled with medications, both acutely (8%) and in the long term (9.1%). CONCLUSIONS: The current series is the largest modern series of PSRS for cerebral AVMs. PSRS can achieve a high obliteration rate with minimal morbidity. Post-treatment hemorrhage remains a potentially fatal risk among patients who have not yet responded to treatment.
Authors: Ahmed J Awad; Brian P Walcott; Christopher J Stapleton; Dale Ding; Cheng-Chia Leed; Jay S Loeffler Journal: J Clin Neurosci Date: 2015-04-23 Impact factor: 1.961
Authors: Jan Unkelbach; Marc R Bussière; Paul H Chapman; Jay S Loeffler; Helen A Shih Journal: Int J Radiat Oncol Biol Phys Date: 2016-02-06 Impact factor: 7.038
Authors: Maria Correia de Verdier; Elisabeth Ronne-Engström; Ljubisa Borota; Kristina Nilsson; Erik Blomquist; Johan Wikström Journal: Acta Radiol Open Date: 2021-11-01
Authors: Christopher S Graffeo; Arjun Sahgal; Antonio De Salles; Laura Fariselli; Marc Levivier; Lijun Ma; Ian Paddick; Jean Marie Regis; Jason Sheehan; John Suh; Shoji Yomo; Bruce E Pollock Journal: Neurosurgery Date: 2020-09-01 Impact factor: 4.654